Patrick Morris
President at Paragon Biosciences Emalex Capital, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jeffrey Aronin | M | 56 |
OVATION Pharmaceuticals, Inc.
 OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL.
Paragon Biosciences Qlarity Capital, Inc.
 Paragon Biosciences Qlarity Capital, Inc. Pharmaceuticals: MajorHealth Technology Paragon Biosciences Qlarity Capital, Inc. provides pharmaceutical services. The company was founded in 2018 and is headquartered in Chicago, IL.
Paragon Biosciences Emalex Capital, Inc.
 Paragon Biosciences Emalex Capital, Inc. Pharmaceuticals: MajorHealth Technology Paragon Biosciences Emalex Capital, Inc. provides pharmaceuticals services. The company is headquartered in Northbrook, IL.
Paragon Biosciences Skyline Capital LLC
 Paragon Biosciences Skyline Capital LLC Pharmaceuticals: MajorHealth Technology Paragon Biosciences Skyline Capital LLC engages in the provision of pharmaceutical services. The company is headquartered in Northbrook, IL.
CIRC Biosciences, Inc.
 CIRC Biosciences, Inc. BiotechnologyHealth Technology CIRC Biosciences, Inc. is a privately held cell therapy company that focuses on developing treatments for serious diseases with high unmet needs. The company is based in Dallas, TX. The company's initial focus is on the eye. The company was founded by Jeffrey S. Aronin.
Castle Creek Biosciences, Inc.
 Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 16 years |
| Timothy Cunniff | M | - |
OVATION Pharmaceuticals, Inc.
OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL.
CIRC Biosciences, Inc.
CIRC Biosciences, Inc. BiotechnologyHealth Technology CIRC Biosciences, Inc. is a privately held cell therapy company that focuses on developing treatments for serious diseases with high unmet needs. The company is based in Dallas, TX. The company's initial focus is on the eye. The company was founded by Jeffrey S. Aronin.
Paragon Biosciences Skyline Capital LLC
Paragon Biosciences Skyline Capital LLC Pharmaceuticals: MajorHealth Technology Paragon Biosciences Skyline Capital LLC engages in the provision of pharmaceutical services. The company is headquartered in Northbrook, IL.
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 8 years |
| Antonio Gracias | M | 53 |
Paragon Biosciences Qlarity Capital, Inc.
Paragon Biosciences Qlarity Capital, Inc. Pharmaceuticals: MajorHealth Technology Paragon Biosciences Qlarity Capital, Inc. provides pharmaceutical services. The company was founded in 2018 and is headquartered in Chicago, IL.
Paragon Biosciences Emalex Capital, Inc.
Paragon Biosciences Emalex Capital, Inc. Pharmaceuticals: MajorHealth Technology Paragon Biosciences Emalex Capital, Inc. provides pharmaceuticals services. The company is headquartered in Northbrook, IL.
CIRC Biosciences, Inc.
CIRC Biosciences, Inc. BiotechnologyHealth Technology CIRC Biosciences, Inc. is a privately held cell therapy company that focuses on developing treatments for serious diseases with high unmet needs. The company is based in Dallas, TX. The company's initial focus is on the eye. The company was founded by Jeffrey S. Aronin.
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 6 years |
| Michael Derby | M | 51 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 9 years |
| Matthew Gantz | M | 59 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 3 years |
| Jeremy Cress | M | - |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | - |
| Jeffrey G. Hesselberg | M | 65 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 4 years |
| Mary Spellman | M | 62 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 4 years |
| Andrea Kistner | F | - |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 4 years |
| Babar Ghias | M | 45 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | - |
| Sai Chavala | M | - |
CIRC Biosciences, Inc.
CIRC Biosciences, Inc. BiotechnologyHealth Technology CIRC Biosciences, Inc. is a privately held cell therapy company that focuses on developing treatments for serious diseases with high unmet needs. The company is based in Dallas, TX. The company's initial focus is on the eye. The company was founded by Jeffrey S. Aronin. | - |
| Edward Russell | M | - |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | - |
| Tymissha Jackson | M | - |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | - |
| Mark Graf | M | - |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jeffrey Whitnell | M | 68 |
OVATION Pharmaceuticals, Inc.
OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL. | 2 years |
| Kevin Gaughan | M | - |
DePaul University
| 8 years |
| Patrick D. Quinn | M | - |
DePaul University
| 1 years |
| John Gray | M | - |
DePaul University
| 6 years |
| Sean Nolan | M | 56 |
OVATION Pharmaceuticals, Inc.
OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL. | 5 years |
| Mark Carlson | M | - |
DePaul University
| 6 years |
| Geraldine Conn | F | 73 |
DePaul University
| 7 years |
| Mark N. Odegard | M | - |
DePaul University
| 4 years |
| Thomas Filarski | M | - |
DePaul University
| 4 years |
| George Burkley | M | - |
DePaul University
| 2 years |
| Andre S. LaBerge | M | - |
DePaul University
| 3 years |
| Jim Leonard | M | - |
DePaul University
| 4 years |
| John Woolway | M | - |
DePaul University
| 2 years |
| Bob J. Vechiola | M | - |
DePaul University
| 3 years |
| Martin R. Castro | M | - |
DePaul University
| 4 years |
| Timothy L. Ford | M | 67 |
DePaul University
| 2 years |
| Joe Riccardo | M | - |
DePaul University
| 4 years |
| William J. Lump | M | - |
DePaul University
| 3 years |
| John R. Kerschen | M | - |
DePaul University
| 2 years |
| Peter J. Shimkus | M | - |
DePaul University
| 4 years |
| Jonathan A. Koff | M | - |
DePaul University
| 3 years |
| Yongyuth Tariyo | M | 73 |
DePaul University
| 1 years |
| Lisa Somlo | F | - |
DePaul University
| 3 years |
| Debbie Bills | F | - |
DePaul University
| 4 years |
| Karla Violetto | F | - |
DePaul University
| 4 years |
| Jessica Garcia-Adams | F | - |
DePaul University
| 4 years |
| Carolyn Schwaar | F | - |
DePaul University
| 4 years |
| Tom Filarski | M | - |
DePaul University
| 4 years |
| Rita Sawyer | F | - |
DePaul University
| 4 years |
| John Kasperski | M | - |
DePaul University
| 4 years |
| Gery Joseph Sadzewicz | M | - |
DePaul University
| 4 years |
| Richard E Peterson | M | - |
DePaul University
| 4 years |
| Sarah Johnson | F | - |
DePaul University
| 4 years |
| Tony Dimaso | M | 54 |
DePaul University
| 4 years |
| Phil Kosmala | M | 53 |
DePaul University
| 4 years |
| James Robinson | M | 54 |
DePaul University
| 4 years |
| James Gerald Walsh | M | 69 |
DePaul University
| 3 years |
| James Harper | M | - |
DePaul University
| 3 years |
| Jahja Anwar | M | 61 |
DePaul University
| 2 years |
| Anne Marie Morley | F | - |
DePaul University
| 4 years |
| John Walding | M | - |
DePaul University
| 2 years |
| Joe Zabratanski | M | - |
DePaul University
| 4 years |
| Vineeta D. Raketich | F | - |
DePaul University
| 4 years |
| Steven Robert Gerbel | M | 54 |
DePaul University
| 6 years |
| Tony Langford | M | 58 |
DePaul University
| 4 years |
| Samuel J. Coady | M | - |
DePaul University
| 4 years |
| Diane L. Mustain | F | - |
DePaul University
| 2 years |
| Kevin J. Kehres | M | - |
DePaul University
| - |
| Daniel Khoshaba | M | 64 |
DePaul University
| 4 years |
| John A. Boselli | M | - |
DePaul University
| 2 years |
| Laurie A. Fishbein | F | - |
DePaul University
| 2 years |
| Barbara K. Sassen | F | - |
DePaul University
| 2 years |
| Beth Tryon | F | - |
DePaul University
| 2 years |
| Todd L. Peters | M | - |
DePaul University
| 2 years |
| Peter Goldman | M | - |
DePaul University
| 2 years |
| Steve Weinstein | M | - |
DePaul University
| 3 years |
| Gregory Schiffman | M | 67 |
DePaul University
| 4 years |
| Deborah Koch | F | - |
DePaul University
| 2 years |
| David Sveen | M | 67 |
DePaul University
| 2 years |
| Austin M. Long | M | 79 |
DePaul University
| 3 years |
| Diane Pearse | F | 66 |
DePaul University
| 2 years |
| Roxane W. Helstrom | F | 67 |
DePaul University
| 2 years |
| Lawrence W. Johnson | M | 57 |
DePaul University
| 4 years |
| Dana I. Green | F | 74 |
DePaul University
| 1 years |
| Karen Joy Scott | F | - |
DePaul University
| 2 years |
| Brian Martin | M | - |
DePaul University
| 4 years |
| Arthur W. Roehm | M | - |
DePaul University
| 2 years |
| Michael J. Barrett | M | - |
DePaul University
| 1 years |
| Irene C. Moroko | F | - |
DePaul University
| 4 years |
| Timothy J. Kroll | M | - |
DePaul University
| 4 years |
| R. Cabell Morris | M | - |
DePaul University
| 3 years |
| Bienvenido C. Salas | M | - |
DePaul University
| 4 years |
| Susan Fillichiio | F | - |
DePaul University
| 3 years |
| Jean Cawley | F | - |
DePaul University
| 3 years |
| David J. Fikse | M | - |
DePaul University
| 2 years |
| John Koufis | M | - |
DePaul University
| 4 years |
| Marija Tatic | F | - |
DePaul University
| 3 years |
| Brian Rosen | M | - |
DePaul University
| 4 years |
| Timothy Condon | M | - |
DePaul University
| 2 years |
| Nicolas P. Liakopulos | M | - |
DePaul University
| 4 years |
| Andrew J. Cederoth | M | 59 |
DePaul University
| 2 years |
| Chuck LeMantia | M | - |
DePaul University
| 2 years |
| David P. Glatz | M | - |
DePaul University
| 4 years |
| Nancy Corrie | F | - |
DePaul University
| 4 years |
| Robert J. Wild | M | - |
DePaul University
| 1 years |
| William Vernon | M | 57 |
DePaul University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Patrick Morris
- Personal Network
